By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gentronix today said that it has signed a three-year deal with GlaxoSmithKline, under which it will provide the drug maker with its GeneScreen HC and BlueScreen HC genotoxicity assays.

The Manchester, UK-based assay developer said that the agreement extends a pact with GSK for the GreenScreen HC to include the BlueScreen HC in 384-well format, which is its latest human cell reporter-based assay for compound profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.